Abstract
Introduction
Dyspnea has been defined as "a subjective experience of breathing discomfort that consists of qualitatively distinct sensations varying in intensity. The experience derives from interactions among multiple physiological, psychological, social, and environmental factors." 1 A common experience among people with life-limiting illness, dyspnea prevalence has been reported to be as high as 65%, 70%, and 90% in advanced-stage patients with heart failure, lung cancer, and chronic obstructive pulmonary disease, respectively. 2 Dyspnea is often intractable in advanced disease, frequently escalating in intensity as death approaches, [3] [4] [5] [6] eroding quality of life, psychological well-being, and social functioning. 7 Dyspnea assessment has been an active area of research for many decades. The complex etiology of dyspnea, both pathophysiological and psychosocial, has proven challenging in developing tools that capture its multiple dimensions. Several recent reviews have examined existing validated measurement tools, highlighting the lack of consensus regarding how to best capture the complicated experience of dyspnea in both clinical and research settings. 8, 9 The spectrum of measures includes single-item ordinal scales, functional assessment scales, global symptom inventories with dyspnea components, and multidimensional dyspnea scales.
The choice of scale depends on purpose, setting, and population. When precision and responsiveness to change are needed, complex multi-item scales may be preferable. 10 However, there are a range of scenarios where single-item dyspnea assessment scales are more appropriate, such as when part of routine clinical care, embedded in a larger group of patient-reported outcomes, or completed repeatedly at short intervals. Among single-item patient-reported scales, the Visual Analogue Scale, 11 Numerical Rating Scale (NRS, e.g., 0 = no breathlessness to 10 = worst breathlessness possible), 12, 13 and the modified Borg scale 14, 15 have all been validated, but none have been preferentially adopted.
The proliferation of assessment tools without standardized adoption of any single tool highlights the need for a simple breathlessness scale that can be reliably and practically used in the clinic, efficiently translating evidence between clinical care and clinical trials. Such a tool should be easily understood across diseases and settings, including advanced lifelimiting illness, and by patients and their families. To achieve this, it must focus on the subjective sensation of dyspnea and parallel other scales commonly used (e.g., pain assessment).
Wilcock et al. 13 advocated that the NRS is more practical than the Visual Analogue Scale for repeated measures in cancer patients. However, ordered categorical scales (e.g., none, mild, moderate, or severe) may be even more practical, would more clearly communicate what is meant clinically, and are less abstract for patients, especially if there is any cognitive impairment. For example, an ordered categorical scale is frequently used for pain assessment, and its relationship to the 0-10 NRS is well characterized (Fig. 1) , although minor differences in cutpoints exist, depending on population and methods. [16] [17] [18] The cutpoint between mild/moderate is often used as a lower threshold limit for eligibility in symptom controlled trials. 19, 20 The aim of this article, therefore, was to determine the relationship between an ordered categorical Verbal Descriptor Scale (VDS) of dyspnea and the dyspnea NRS, in a similar way that these two scales are related for pain assessment.
Methods
This was an a priori planned substudy intentionally embedded within an international, multicenter, double-blind, randomized controlled trial assessing the effect of palliative oxygen vs. room air in relief of refractory dyspnea. 21 The parent study protocol was approved by the Duke University Health System Institutional Review Board, all nine local research and ethics committees or institutional review boards of all participating sites, and was registered with ClinicalTrials.gov (NCT00327873) and International Standard Randomised Controlled Trial Number (ISRCTN) (ISRCTN67448752).
Participants
In the parent study, patients (N = 239) were recruited from pulmonary, palliative care, oncology, and primary care services at five sites in Australia, two in the U.S., and two in the U.K. Participants were consenting adults with refractory dyspnea, partial pressure of oxygen in arterial blood (PaO 2 ) >55 mmHg, and life-limiting illness where the underlying cause had been maximally treated. Participants had dyspnea at rest or with minimal exertion, corresponding to a Medical Research Council categorical dyspnea score of ≥3; 22 however, patient data were pooled for this project, and there was no analysis according to the intervention used for the parent study. Additional eligibility criteria were that the participants must have been on stable medications for the seven days before randomization; hemoglobin >10 gm/dL; prognosis for survival of at least one month; and ability to complete the symptom diary, including ability to sufficiently understand English. Participants were randomized to medical air or oxygen, delivered at 2 L per minute via nasal cannula, for at least 15 hours daily for seven days.
Outcomes
The primary outcome was breathlessness right now, recorded by the participant twice a day (within 30 minutes of waking up [morning] and going to bed [evening] ) in a diary with a 0-10 NRS, anchored at 0 = not breathless at all and 10 = breathlessness as bad as you can imagine, which is a valid instrument for this population of patients. 23 In addition to the dyspnea NRS scale, participant diaries also included a four-point VDS for dyspnea severity (none, mild, moderate, or severe).
Thus, participants answered the following questions daily on both the NRS and VDS scales:
1.
Morning assessment: How is your breathlessness right now?
2.
Evening assessment: How is your breathlessness right now?
3.
Evening assessment: How has your breathlessness been over the last 24 hours, on average?
4.
Evening assessment: What is the worst your breathlessness has been over the last 24 hours?
The participants were not instructed to respond to the questions in a specific order or to rate each scale independently; the daily diary provided to participants was ordered as shown previously. Participants were not asked to distinguish between the somatosensory intensity, affective distress, or other contributors to the perception of dyspnea in rating this item.
Related symptoms, such as anxiety, functional limitations, and quality of life, were assessed with subsequent items in the diary.
For convenience, the preceding questions will henceforth be referred to as follows: Question 1: "AM now," Question 2: "PM now," Question 3: "24 hours average," and Question 4: "24 hours worst." The intervention comparing palliative oxygen and medical air lasted seven days, but patients began maintaining symptom diaries two days before the start of the intervention, thus documenting symptoms twice daily for nine days total.
Statistical Analysis
The relationship between the NRS and VDS responses for each of the four questions described previously was examined two ways: crosssectionally, using a single baseline time point (morning assessment on the day before the study intervention started, labeled Day −1) and longitudinally, across all time points. For the cross-sectional analysis, only participants who responded to both NRS and VDS forms of the question were included. For the longitudinal analysis, we created a single cross-tabulation of NRS and VDS scores regardless of question or time point (i.e., thus implicitly ignoring for the present purposes the multiple observations per patient). Descriptive statistics were used to evaluate and portray relationships. In both the cross-sectional and longitudinal analyses, missing data were not imputed. Although responses for both VDS and NRS were collected longitudinally throughout the study period, the purpose of this substudy was not to compare the responsiveness to change these rating scales. might be translated as mild in the VDS according to the derived cutpoints, but the patient had reported moderate dyspnea corresponding to this instance.
Results
Of the 239 participants, 61.5% were males and 63.5% had a diagnosis of chronic obstructive pulmonary disease (Table 1) . Thirteen patients withdrew before the study started and completed no assessments and, therefore, were excluded from analysis. An additional 15 participants withdrew before completing the final assessment. Across the entire study period, 3.3% of morning NRS assessments and 3.6% of morning VDS assessments were missingpredominantly because of dropout.
Cross-Sectional Analysis
The NRS and VDS were compared before any intervention (baseline, Day −1 Table 2 ). The NRS ranges that capture increasing percentages of patients in each VDS category were consistent ( Table 2 
Longitudinal Analyses
Combining responses to all four questions across all nine days of the study yielded 3882 paired observations for NRS and VDS. The results of analyses were substantively similar to those from the cross-sectional analysis of the AM now assessment on Day −1. The distribution of NRS scores within VDS categories is similar to that observed for the AM now assessment on Day −1 (Fig. 2) . Specifically, the mean (SD) NRS scores were 0.61 (1.0) for VDS none, 3.4 (1.5) for VDS mild, 5.8 (1.4) for VDS moderate, and 8.2 (1.5) for VDS severe. The Spearman correlation coefficient for the VDS and NRS ratings was 0.78.
Cutpoint Analyses
Using the longitudinal data, analysis of the distribution of VDS category by NRS reveals that 94% of NRS responses of 0 correspond to VDS reports of none (Fig. 2) . Based on the distribution of NRS scores within VDS categories, we examined the performance characteristics of two different cutpoint models. For Model A, NRS 0 corresponded to VDS none, NRS 1-4 corresponded to VDS mild, NRS 5-8 corresponded to VDS moderate, and NRS 9-10 corresponded to VDS severe. In Model B, NRS 0 corresponded to VDS none, NRS 1-5 corresponded to VDS mild, NRS 6-8 corresponded to VDS moderate, and NRS 9-10 corresponded to VDS severe (Table 2 ). Both models had a roughly 75% rate of correct translations from NRS to VDS; however, Model A had fewer misses downcoded (e.g., where the NRS attributed a lower VDS than the patient had reported at the corresponding time). Model A yields an 87% sensitivity and 78% specificity for moderate or severe dyspnea, whereas Model B yields only a 63% sensitivity but is more specific at 93% (Table 3) .
Discussion
VDSs are practical tools for dyspnea monitoring in the clinic when more complicated scales such as a full 0-10 NRS may not be feasible. In this analysis, we demonstrate that the dyspnea VDS performs as expected, with tight clustering of NRS scores within VDS categories. Corresponding VDS and NRS scores have face validity.
In translating NRS to VDS, identification of NRS cutpoints for the transition from mild to moderate or moderate to severe is an important consideration. In pain, cutpoint identification has been addressed in multiple studies, across multiple disease states. 24 In general, most studies yielded cutpoints identical to those identified by Serlin et al., 16 who used functional impairment to inform on pain severity in patients with metastatic cancer. The optimal NRS ranges identified in that study were 1-4 for mild, 5-6 for moderate, and 7-10 for severe. The consistency and similarities between the VDS for pain and ours for dyspnea suggest that verbal rating scales may have better inter-rater reliability. As shown previously in pain and confirmed here, there appears to be a uniform semantic meaning of the verbal descriptors mild, moderate, and severe. 25, 26 Notably, these verbal descriptors and their numerical associations differ from the modified Borg scale.
For dyspnea, we have identified reasonable clustering of NRS scores among VDS categories and established practical cutpoints. Based on the transition points (Fig. 2 ), in combination with the comparative performance characteristics, we propose the following cutpoints: 0 for none, 1-4 for mild, 5-8 for moderate, and 9-10 for severe (Table 3 , Model A; Fig. 3 ). The cutpoints from none to mild and moderate to severe, based on the distribution of responses, are straightforward. The cutpoint from mild to moderate is less clear, though, because of the nearly even distribution of VDS and NRS around this transition. We made the recommendation for a mild to moderate cutpoint of 5 based on the superior sensitivity of this cutpoint to minimize downgrading. Clinically, downgrading symptom severity poses the risk of leaving clinical needs unaddressed, which is potentially more harmful than overestimating symptom burden. Of course, this consideration also must be balanced against the potential of exposing patients to unnecessary treatments if their symptoms are upgraded.
data, numerical differences between pairs of subsequent verbal descriptors are equal (Table  2) , which may allow subsequent analyses to treat these VDS categories as interval variables, rather than ordinal, where this is appropriate. This provides practical opportunities for analyses when the VDS is incorporated into clinical research and quality monitoring programs.
The parallels we have drawn between pain and dyspnea are supported elsewhere in the literature, 27 especially in light of growing evidence for dyspnea management strategies that parallel pain management strategies such as opioids. 28 Similarly, there is more focus on integrated assessment and care models for dyspnea that parallel pain. For example, total breathlessness describes the concept whereby, like pain, breathlessness is experienced as an amalgamation of physical, psychosocial, and spiritual problems. 25 This concept is supported by involvement of both cortical and subcortical central pathways in the perception of breathlessness, 26, 29 with strong similarities with those involved in the perception of pain and similar patterns demonstrated by functional magnetic resonance imaging. 30 Pain management has become an integral component of most clinical assessments, but only after consensus regarding routine pain assessment tools was achieved. Similarly, as therapeutic options for dyspnea evolve, widespread clinical implementation will depend on ubiquitous and longitudinal dyspnea assessment using a simple, intuitive, and practical tool. 31 The VDS and NRS are intended to fill this role, with the VDS being the most practical and efficient, and the NRS most useful when more fine-tuned information is needed. For purposes of simplicity, we anticipate that some health care providers, health systems, or electronic health records may choose to adopt the VDS for routine monitoring of dyspnea.
Beyond being simple, intuitive, and practical, the VDS scale and the proposed corresponding NRS cutpoints have implications for efficacy trials. In many pain management efficacy trials, the cutpoint for inclusion is the NRS cutpoint corresponding to moderate pain. 19, 20 Considering the VDS to NRS cutpoints for moderate dyspnea identified in this study (i.e., moderate dyspnea corresponds to a starting point of NRS of 5), it is sensible to use an NRS of 5 or greater as a practical eligibility criterion for trials of novel dyspnea therapeutic interventions. Despite the distributional overlap between mild and moderate dyspnea, this cutpoint yields an 87% sensitivity and 78% specificity for moderate or severe dyspnea. If some enrolling centers use an NRS, whereas others use a VDS, understanding this relationship may be useful in screening records for recruitment or informing multicenter research.
This study has several limitations. As has previously been described, VDSs offer less granularity, are unidimensional, and may be insufficiently sensitive to detect small, but potentially meaningful, changes in symptom severity. 32 Further work is needed to better characterize the reliability, validity, responsiveness, and determine clinically relevant changes of this VDS for breathlessness, all of which are beyond the scope of this analysis. Additionally, the assumption that increments between each ordinal category are numerically similar is frequently cited as a limitation of VDSs. In this study, however, the difference in mean NRS score for each VDS category was very consistent ( Table 2 ), suggesting that, at least from a population standpoint, there is a consistent incremental stepwise relationship between the VDS categories. One limitation of single-item scales is that they can be influenced by the affective experience of dyspnea and may not completely isolate the somatosensory intensity of dyspnea. These instruments are not designed to discriminate between the various contributors to dyspnea (e.g., pulmonary disease, mood disturbance, lack of social support, existential distress). It has been demonstrated that single-item ratings of pain are more reflective of psychosocial distress than pathophysiologic processes. 33 Neither the parent study nor this substudy intended to evaluate the primary drivers of the experience of breathlessness. Thus, heterogeneity in the components of breathlessness between participants is likely; in fact, there was marked heterogeneity among the diagnoses driving the breathlessness in this study. These scales are not intended to replace such instruments in research protocols where the components of breathlessness are of interest.
As dyspnea management continues to evolve, implementation of an assessment tool that is clinically practical and intuitive is necessary. We have demonstrated good correlation between verbal descriptor and NRSs for dyspnea in a population with life-limiting illness and refractory dyspnea and have identified practical cutpoints relating the NRS to VDS. These scales are practical and clinically intuitive and can be easily integrated into routine clinical practice and provide cutpoints that can be used to screen for inclusion in clinical dyspnea management trials. Practical relationships between Numerical Rating Scale and Verbal Descriptor Scale for pain (top, based on results from Refs. 15, 16 ) and breathlessness (bottom, based on this study). c Percent of patients where the NRS attributed a lower VDS than the patients attributed themselves.
